| NCT07156578 | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) | NOT_YET_RECRUITING | PHASE2 | 2025-11-03 | 2028-04-15 | 2028-04-15 |
| NCT06760546 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | RECRUITING | PHASE3 | 2025-09-23 | 2027-01-30 | 2027-01-30 |
| NCT06772597 | A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome | RECRUITING | PHASE2 | 2025-03-04 | 2026-01-31 | 2026-01-31 |
| NCT06596135 | Open-Label Extension Study of Setmelanotide | ENROLLING_BY_INVITATION | PHASE3 | 2024-10-21 | 2027-10-30 | 2027-10-30 |
| NCT06046443 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-07-11 | 2026-01-31 | 2026-01-31 |
| NCT06239116 | A Study of RM-718 in Healthy Subjects and in Patients With HO | RECRUITING | PHASE1 | 2024-03-05 | 2026-05-04 | 2026-05-04 |
| NCT05774756 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-04-26 | 2027-04-16 | 2025-03-18 |
| NCT04966741 | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | COMPLETED | PHASE3 | 2022-03-08 | 2024-11-08 | 2023-09-18 |
| NCT05194124 | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | COMPLETED | PHASE3 | 2021-12-21 | 2023-10-19 | 2023-10-19 |
| NCT05093634 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-12-10 | 2025-12 | 2025-12 |
| NCT04963231 | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | COMPLETED | PHASE2 | 2021-11-30 | 2024-09-30 | 2023-08-04 |
| NCT05046132 | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants | COMPLETED | PHASE4 | 2021-08-05 | 2022-04-07 | 2022-04-07 |
| NCT04725240 | Open-Label Study of Setmelanotide in Hypothalamic Obesity | COMPLETED | PHASE2 | 2021-06-07 | 2022-06-28 | 2022-06-28 |
| NCT04348175 | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment | COMPLETED | PHASE1 | 2020-07-09 | 2021-04-17 | 2021-04-17 |
| NCT03746522 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | COMPLETED | PHASE3 | 2018-11-23 | 2021-03-08 | 2020-11-16 |
| NCT03651765 | Long Term Extension Trial of Setmelanotide | COMPLETED | PHASE2, PHASE3 | 2018-07-15 | 2025-01-09 | 2025-01-09 |
| NCT03287960 | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | COMPLETED | PHASE3 | 2018-01-30 | 2020-09-25 | 2020-09-25 |
| NCT03262610 | Setmelanotide in a Single Patient With Partial Lipodystrophy | COMPLETED | PHASE2 | 2017-08-15 | 2018-01-31 | 2018-01-31 |
| NCT02896192 | Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity | COMPLETED | PHASE3 | 2017-02-14 | 2020-05-25 | 2020-05-25 |
| NCT03013543 | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | COMPLETED | PHASE2 | 2017-02-10 | 2022-03-01 | 2022-03-01 |
| NCT02311673 | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | COMPLETED | PHASE2 | 2015-03-19 | 2016-10-26 | 2016-10-26 |
| NCT02041195 | Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients | COMPLETED | PHASE1, PHASE2 | 2014-01 | 2014-12 | 2014-08 |
| NCT01867437 | Effects of RM-493 on Energy Expenditure in Obese Individuals | COMPLETED | PHASE1 | 2013-05 | 2014-03 | 2014-03 |
| NCT01749137 | Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | COMPLETED | PHASE2 | 2013-01-14 | 2013-09-28 | 2013-09-28 |
| NCT02431442 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers | COMPLETED | PHASE1 | 2012-01 | 2014-01 | 2014-01 |